Clinical Study of Redirected Autologous T Cells With a GPC3-targeted Chimeric Antigen Receptor in Patients With Refractory Hepatocellular Carcinoma
Phase of Trial: Phase I
Latest Information Update: 23 Jun 2017
At a glance
- Drugs GPC3-CAR-T (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Pharmacokinetics
- 23 Jun 2017 According to a CARsgen Therapeutics media release, data from this trial presented at the 2017 BIO International Convention 2017.
- 05 May 2017 Planned End Date changed from 19 Dec 2019 to 15 Jun 2020.
- 22 Nov 2016 New trial record